G551D mutation, only approximately 3000 patients might be able to benefit from the new drug. The costs for one year of treatment with KalydecoTM
$294,000 in the US or €306,000 (reference price in Germany) respectively, making it pricey. The time between the discovery of ivacaftor and the marketing authorisation was short, but filled with complexities. The development was partly sponsored by a charity. Even if we assume a total cost of development for KalydecoTM
billion US$ and that only every third CF patient with a G551D mutation would in fact receive the branded drug, the return on investment would be reached within three years. Clearly, some of the sales returns will be used as royalties to the CFF and to help developing other compounds directed against the remaining 96% of mutations found in those CF patients who may not benefit from ivacaftor. But questions might be raised whether the public insurance systems are willing to support a lifelong therapy with orphan drugs such as KalydecoTM
. Countries such as Germany 22 and the UK require that an added benefit www.hospitalpharmacyeurope.com
for every newly approved drug over pre-existing therapies is demonstrated in order for it to be reimbursed through the public insurance system.
The future will tell whether ivacaftor is, in fact, the quantum leap innovation to justify the costs. However, from the perspective of someone who has spent half of his lifetime waiting for a drug that treats the basic defect in CF, ivacaftor is certainly a major leap forward. l
References 1. Kerem B et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245(4922):1073–80.
2. Griesenbach U, Geddes DM, Alton EWFW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2006;13(14):1061–7.
3. Kunzelmann K et al. Role of the Ca2+ Cl-
channels bestrophin and anoctamin in epithelial cells. Biol. Chem 2011;392(1–2):125–34.
4. Erlinge D. P2Y receptors in health and disease. Adv Pharmacol 2011;61:417–39.
5. Ratjen F et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 2012;11(6):539–49.
6. Grasemann H et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007;131(5):1461–6.
7. Clancy JP et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67(1):12–18.
8. Bompadre SG, Sohma Y, Li M, Hwang T-C. G551D and G1349D, Two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J Gen Physiol 2007;129(4):285–98.
9. Beall R. Straight talk with... Robert Beall. Interviewed by Elie Dolgin. Nat Med 2012;18(3):335.
10. Van Goor F et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106(44):18825–30.
11. Accurso FJ et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363(21):1991–2003.
12. Ramsey BW et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663–72.
13. Gever J. FDA approves cystic fibrosis drug. www. medpagetoday.com/article.cfm?tbid=30936
(accessed 22 January 2013).
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24